Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy by unknown
Williams et al. Journal of Experimental & Clinical Cancer Research 2013, 32:57
http://www.jeccr.com/content/32/1/57RESEARCH Open AccessRenal cancer-selective Englerin A induces
multiple mechanisms of cell death and
autophagy
Richard T Williams1, Alice L Yu1,2,3, Mitchell B Diccianni1, Emmanuel A Theodorakis4 and Ayse Batova4*Abstract
Renal cell carcinoma (RCC), the most common malignancy of the kidney, is refractory to standard therapy and has
an incidence that continues to rise. Screening of plant extracts in search of new agents to treat RCC resulted in the
discovery of englerin A (EA), a natural product exhibiting potent selective cytotoxicity against renal cancer cells.
Despite the establishment of synthetic routes to the synthesis of EA, very little is known about its mechanism of
action. The results of the current study demonstrate for the first time that EA induces apoptosis in A498 renal
cancer cells in addition to necrosis. The induction of apoptosis by EA required at least 24 h and was caspase
independent. In addition, EA induced increased levels of autophagic vesicles in A498 cells which could be inhibited
by nonessential amino acids (NEAA), known inhibitors of autophagy. Interestingly, inhibition of autophagy by NEAA
did not diminish cell death suggesting that autophagy is not a cell death mechanism and likely represents a cell
survival mechanism which ultimately fails. Apart from cell death, our results demonstrated that cells treated with EA
accumulated in the G2 phase of the cell cycle indicating a block in G2/M transition. Moreover, our results
determined that EA inhibited the activation of both AKT and ERK, kinases which are activated in cancer and
implicated in unrestricted cell proliferation and induction of autophagy. The phosphorylation status of the cellular
energy sensor, AMPK, appeared unaffected by EA. The high renal cancer selectivity of EA combined with its ability
to induce multiple mechanisms of cell death while inhibiting pathways driving cell proliferation, suggest that EA is
a highly unique agent with great potential as a therapeutic lead for the treatment of RCC.
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Renal cell carcinoma (RCC) is the most common type of
malignant kidney tumor with an incidence that con-
tinues to rise. Between 1992 and 2005, the incidence of
RCC rose by 1.8% and 2.1% among white men and white
women, respectively [1]. Although surgery can be cura-
tive for tumors confined to the kidney, about 25% of pa-
tients have metastatic disease at diagnosis, and another
20-40% develop metastases following surgery [2,3]. The
two-year survival rate for patients with metastatic dis-
ease is under 20% due to the poor response of these tu-
mors to current treatments. Clear cell RCC (cc-RCC)
which comprises 83% of RCC is one of the most radio-* Correspondence: abatova@ucsd.edu
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reproduction in any medium, provided the orand chemo-resistant cancers and no curative treatment
is available once metastases develop [4].
Investigations of the molecular biology of RCC have
established that inactivating alterations in the Von
Hippel Lindau (VHL) tumor suppressor gene are present
in the majority (91%) of sporadic cc-RCC underscoring
the central role of VHL in the regulation of growth and
differentiation of renal epithelium [5-7]. The VHL gene
product is involved in oxygen and energy sensing by
regulating the activity of the hypoxia inducible factors
(HIFs) [8]. Inactivation of VHL results in HIF stabilization
and the activation of transcription of over 60 hypoxia-
responsive genes involved in oncogenesis and tumor pro-
gression including vascular endothelial growth factor
(VEGF), the platelet-derived growth factor (PDGF),
transforming growth factor alpha (TGF-α), epidermal
growth factor (EGF), and glucose transporter-1 (GLUT-1)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inducible genes, a variety of downstream signaling path-
ways are activated of which the most studied are the
RAF-MEK-ERK series of kinases and the phosphatidylinositol-
3 kinase-protein kinase B-mammalian target of rapamycin
(PI3K-AKT-mTOR) pathway [11]. Based on the activa-
tion of these pathways in RCC, several targeted therap-
ies have been developed including those against VEGF
and PDGF receptors, and mTOR. However, despite the
promise of approved targeted therapies for RCC, a
complete response is rare and patients often become
resistant/refractory to first line treatment [3,12]. Thus,
new agents with improved efficacy and decreased tox-
icity are needed as treatment options in first line or
subsequent settings.
The need to identify new chemical motifs as potential
drug leads has spurred the screening of plant extracts
that are being used in traditional medicines [13,14]. In
particular, South Africa has a remarkable botanical
diversity with over 30,000 flowering species, from which
more than 3,000 are used for medicinal purposes through-
out the country. Among them, plants of the genus
Phyllanthus (Euphorbiaceae) are widely distributed in
tropical forests throughout the world and have long been
used in folk medicine to treat kidney and urinary tract
infections [15]. Based on this knowledge, Ratnayake
et al. [16] at the NCI screened extracts of the Tanza-
nian plant Phyllanthus engleri and have reported the
isolation of two novel bioactive sesquiterpenes, named
englerin A (EA) and englerin B. Initial studies by the
NCI demonstrated that EA possessed very potent
growth inhibitory activity (GI50 = 10–87 nM) against
most RCC with a selectivity that is approximately
1,000-fold higher compared to other cancers.
Although several synthetic routes toward the synthesis
of EA have been established [16-21], other than EA’s
selective toxicity to RCC, recently confirmed by us
[21], very little is known about its biological actions
and mechanism(s) of action. Only recently, one study
reported that EA induced necrosis in RCC [22]. The
most recent report concluded that EA bound and acti-
vated protein kinase C-θ (PKCθ) to inhibit insulin sig-
naling while, concurrently, activating HSF1, a known
inducer of glucose dependence [23]. This dual signaling,
that promotes glucose addiction while inhibiting glucose
uptake by the cells, was proposed to be the mechanism
for the selective cytotoxicity of EA. Although the data
presented is compelling, whether in fact this mechanism
accounts for the cytotoxicity of EA is not yet clear.
Based on its cytotoxicity profile against the NCI60 cell
panel, EA is clearly a very unique agent and there is
much to be learned about the actions of EA in RCC and
the mechanisms and targets involved in these actions. In
this study, using the highly EA-sensitive A498 humanrenal carcinoma cells as our model system, we report
the results of a thorough and systematic investigation to
uncover the mechanisms of growth inhibition and cell
death induced by EA and reveal for the first time that
EA induces multiple mechanisms of cell death as well as
cell cycle arrest while inducing autophagy.
Material and methods
Cell lines
The A498 human kidney carcinoma cell line was pur-
chased from ATCC and maintained in RPMI medium
supplemented with 10% FBS and 100 units/ml penicil-
lin/streptomycin (complete medium).
Reagents
Englerin A was purchased from Cerilliant Corporation.
(Round Rock, Texas). Rapamycin was purchased from
Enzo Life Sciences (Farmingdale, NY) as part of the
Cyto-ID® Autophagy Detection Kit. VP16 was purchased
from Sigma Aldrich (St. Louis, MO). MEM 100X non-
essential amino acids (NEAA) was purchased from
Gibco Life Technologies (Grand Island, NY). Antibody
against caspase-3 was a gift from Dr. Robert Naviaux
and anti LC3B was purchased from Cell Signaling
Technology (Danvers, MA). Antibody against Β-actin
(AC-15) was purchased from Sigma Aldrich (St. Louis,
MO). Antibodies against phospho AMPK (Thr172) and
phospho ERK (Thr202/Tyr204) as well as those for
AMPK and ERK were generous gifts of Dr. R. Naviaux.
The antibodies against AKT and phospho AKT (Ser473)
were purchased from Cell Signaling Technology.
Viability assay
A498 cells were plated at 5,000 cells/well in a 96-well
plate in complete medium. The following day, cells
were treated with EA at 50 and 100 nM. Control cells
received 0.1% DMSO. All conditions were performed in
triplicate. Cells were then incubated with additions for
24 or 48 h before measuring viability using the PrestoBlue®
(Invitrogen, CA) assay as described by manufacturer. This
assay uses a resazurin-based solution that functions as a
cell viability indicator by using the reducing power of liv-
ing cells to quantitatively measure the proliferation of
cells. Viability was determined by measuring fluorescence
on a Synergy Mx plate reader (BioTek Instruments Inc.,
Winooski, VT) with excitation/emission at 560/590 nM.
Apoptosis assays
Apoptosis was determined independently by two differ-
ent methods. The Alexa Fluor® 488 annexin V/Dead Cell
Apoptosis Kit (Life Technologies, Grand Island, NY) was
used to measure externalized phosphatidyl serine and
dead cells permeable to propidium iodide (PI). For these
experiments, A498 cells were treated with 100 nM EA
Williams et al. Journal of Experimental & Clinical Cancer Research 2013, 32:57 Page 3 of 13
http://www.jeccr.com/content/32/1/57or with 0.1% DMSO (control) for 24 and 46 h. Cells
were then trypsinized, washed with ice cold PBS, and
stained with Alexa Fluor® 488 annexin V and PI as
recommended by manufacturer. Cells were then ana-
lyzed by flow cytometry using a FACS Caliber flow
cytometer (Beckton Dickinson, Franklin Lakes, NJ) and
Flow Jo software (TreeStar Inc., Ashland, OR).
Apoptosis induced by EA in A498 cells was also deter-
mined by measuring cytoplasmic histone-associated-DNA-
fragments using the Cell Death Detection ELISAPLUS
kit (Roche Diagnostics GmbH, Mannheim, Germany)
according to the manufacturer’s instructions. In these ex-
periments, A498 cells were plated at 5,000 cells/well (96-
well plate) in complete RPMI medium. The following day,
cells were treated with 100 nM EA or with 0.1% DMSO,
and incubated at 37°C for 18, 24, and 45 h before apoptosis
was measured.Caspase assays
Multiple caspases were analyzed using the FLICA re-
agent (FAM Caspase Activity kit, Imgenex, San Diego,
CA) which only binds active caspases. In these experi-
ments, A498 cells were plated at 0.5 × 106 cells/T-25
flask in complete RPMI. After cells were allowed to at-
tach overnight, cells were treated with 100 nM EA or
0.1% DMSO for 43 h, or with 200 μM etoposide for 24
h. Cells were then harvested and stained with the FLICA
reagent according to manufacturer’s recommendations
and fluorescence was measured with excitation at 490
nm and emission at 520 nm. Caspase-9 activity was
measured after treatment of cells with and without 100
nM EA as above followed by trypsinization and cell lysis.
Caspase-9 activity was then determined using the
Caspase-9 Colorimetric Assay kit (BioVision, Mountain
View, CA) according to protocol provided by manufac-
turer. Absorbance was read at 400 nm. The levels of ac-
tive caspase-3 were determined by Western blot analysis
as described below.Autophagy assays
Autophagy was determined by three different methods
including flow cytometry, fluorescence microscopy and
western blot analysis. For flow cytometry experiments,
A498 cells were plated in T-75 flasks at 1.25 × 106/flask
in complete RPMI. After the cells were allowed to attach
overnight, cell were treated with 200 nM EA or 0.1%
DMSO (control) for 46 h and with 500 nM rapamycin
for 20 h. Autophagy was measured by staining autolysosomes
and earlier autophagic compartments with the fluores-
cent probe Cyto-ID® Green (Enzo Life Sciences, Farmingdale,
NY) as recommended by manufacturer. Samples were
then analyzed in the green (FL1) channel of the FACS
Caliber flow cytometer.For fluorescence microscopy, A498 cells were plated in
complete RPMI on coverslips placed in a 60 mm dish at
1.5 (control cells) to 3.0 × 105 (treated cells) cells/dish.
After the cells were allowed to attach overnight, cell
were treated with 200 nM EA or 0.1% DMSO (control)
for 45 h. Cells were then stained with Hoechst nuclear
stain and Cyto-ID® Green detection reagent using the
Cyto-ID® Autophagy Detection Kit according to recom-
mendations. Cells were fixed with 4% formaldehyde for 20
min at room temp followed by three washes with 1X assay
buffer. Cover slips were then placed on slides with mount-
ing media. Stained cells were analyzed by fluorescence mi-
croscopy (Olympus BX51 microscope that has been
equipped with the fluorescence illuminator BX-URA2)
using an Omega Optical XF100-2 filter for green bandpass
with a 475 nm exciter to image autophagic cells.
Western blot analysis
A498 cells were plated at 1–2 × 106 cells/ T-75 flask in
complete RPMI. After cells were allowed to adhere over-
night, cells were treated with 100, 200 nM EA or with
0.1% DMSO for 48 h before harvesting. Cells were
trypsinized, collected, and resuspended in ice- cold PBS.
Cells were lysed in RIPA buffer (50 mM Tris–HCl pH
8.0, 1% Triton X-100, 150 mM NaCl, 1mM EDTA, 0.5%
Deoxycholate, 0.1% Sodium Dodecyl Sulfate, 1mM
Sodium Fluoride, 1 mM Sodium Pyrophosphate) in the
presence of PMSF and protease inhibitor cocktail.
Lysates were clarified by centrifugation for 15 min
at 10,000×g, 4°C. To the clarified lysate, 4 × NuPAGE
LDS sample buffer (Life Technologies) and 0.05 M
dithiothreitol were added and samples were heated for
10 min at 80°C. Proteins were separated by SDS-PAGE
on a 10% Bis-Tris NuPAGE Gel (Life Technologies)
and then transferred to PVDF membranes (Bio-Rad).
The PVDF membranes were blocked with 5% Bovine
Serum Albumin (Sigma) in TBS with 0.05% Tween-20
and probed with antibodies against caspase-3, (diluted
1:1000), LC3B (diluted 1:1000), and B-actin (diluted
1:50,000). Antibodies against AMPK, AKT, ERK and
against the corresponding phospho proteins were each
diluted 1:1000 except for phospho AKT which was
diluted at 1:500. An HRP-conjugated anti-mouse anti-
body (diluted 1:1000) or HRP-conjugated anti-rabbit
antibody (diluted 1:1000;) was used as a secondary detec-
tion probe. Bands were visualized using ECL enhanced
chemiluminescent substrate (Pierce) and exposed to
HyBlot CL film (Denville Scientific). The film was devel-
oped with a Kodak film developer.
Cell cycle analysis
A498 cells were plated at 2 × 105 (control) or at 4 × 105
(EA treated) cells/flask into T-25 flasks in complete
RPMI. After cells were allowed to attach overnight, cells
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45 h. The cells were then trypsinized, washed with ice-
cold PBS, fixed with ice-cold 70% ethanol at a 1:10 ratio
of cell suspension to 70% ethanol, and stored at -20ºC
overnight. Cells were washed twice with PBS and then
stained with staining solution containing Triton x-100
(0.1% v/v), DNase free RNase (200 μg/ml), PI (30 μg/ml)
in PBS for 15 min at 37ºC. PI content of cells was mea-
sured using a FACS Calibur flow cytometer and cell
cycle distribution was determined using FlowJo analysis
software.
Results
Examination of viability and determination of apoptosis
and necrosis
Examination of the cytotoxicity of EA against multiple
tumor types using the NCI60 cell panel determined that
EA was very selectively toxic to RCC with GI50 concen-
trations ranging from 10–83 nM in most RCC lines [16].
Our own previous studies have also documented this se-
lectivity [21]. We extended these results by conducting
viability studies using one of the most sensitive RCC
lines, A498 cells, and treated them with 50 and 100 nM
EA from 24 to 48 h. The results of these experiments
which measured metabolically active cells, indicated that
although cell death was observed by 24 h at both EA
concentrations, the majority of cell death (> 80% of con-
trol) required greater than 24 h and occurred by 48 h of
treatment (Figure 1A). To confirm these results, as well
as to determine the cell death mechanism(s) involved in
EA-induced cell death, apoptosis was determined by
measuring histone-associated DNA fragments by ELISA
in A498 cells treated with 100 nM EA for 24 and 45 h
(Figure 1B). The induction of apoptosis by EA in A498
cells required at least 24 h for significant levels of apop-
tosis to occur as no apoptosis was observed at 18 h (data
not shown). Additional studies determined that the EA-
induced apoptosis was also dose-dependent (data not
shown). To further confirm that EA induced apoptosis
in A498 cells, apoptosis was also determined by measur-
ing phosphatidylserine exposure on cells using the Alexa
Fluor® 488 annexin V/Dead Cell Apoptosis kit followed
by flow cytometry. The results of these experiments
revealed that EA at 100 nM induced apoptosis in
A498 cells at levels well above control by 46 h of
treatment (Figure 1C). The apoptotic cells included
Annexin V positive (5.2%) as well as Annexin V/PI
double positive (15.4%) cells representing early and late
stages of apoptosis, respectively. In addition, some nec-
rotic, PI positive, only (4.0%), cells were also observed.
Furthermore, cells treated with a clinically relevant
concentration (50 nM) of vincristine, a chemothera-
peutic agent known to induce apoptosis in several
tumor types [24], induced similar levels of necrosis(3.6%), but less than half as much apoptosis (1.2% and
7.5% early and late stages of apoptosis, respectively) as
EA in A498 cells. Higher concentrations of vincristine
were not tested, thus, it is possible that 100 nM vin-
cristine may have induced similar levels of apoptosis
to EA. Overall, our results indicated that EA induced
cell death in A498 cells, the majority of which, oc-
curred after 24 h of treatment, and at least part of this
cell death was due to apoptosis.
Analysis of caspase activity
Having established that EA induced apoptosis in A498
cells, the question remained as to whether caspases were
involved in EA-induced apoptosis and if so which ones
were involved. To determine if EA induced caspase acti-
vation in general, active caspases were measured in
A498 cells, treated as indicated in Figure 2A, by using
the FLICA reagent (Fluorochrome Inhibitor of Caspases)
which binds covalently to only active caspases and al-
lows active caspase detection by fluorescence. The
etoposide, VP16, a chemotherapeutic agent known to in-
duce apoptosis in multiple tumor types and known to
activate caspases [25], was used as a positive control in
these experiments. Because the effective dose of VP16 is
in the micromolar range and since RCC cells are not
nearly as sensitive to VP16 and other standard chemo-
therapeutic agents when compared to EA, higher con-
centrations of VP16 were used in these experiments
over EA. While active caspases were detected in cells
treated with 200 μM VP16, active caspases were not
detected in cells treated with 100 nM EA (Figure 2A), a
concentration of EA reducing cell viability by 70-80%.
To confirm that EA did not induce caspase activation,
levels of active caspase-3, an executioner caspase, were
also determined. Levels of active caspase-3 were exam-
ined by Western Blot analysis in A498 cells treated with
200 nM EA or 0.1% DMSO for 48 h. The results of this
analysis showed no evidence of caspase-3 activation by
EA (Figure 2B) confirming our results using the FLICA
reagent (Figure 2A). Similarly, active caspase-9, a
caspase frequently activated by anti-cancer agents, was
also not detected in A498 cells treated with EA (data not
shown). Altogether, our results indicate that apoptosis
induced by EA in A498 cells occurs in a caspase-
independent manner.
Detection of autophagy
The finding that apoptosis induced by EA in A498 cells
required at least 24 h, even at concentrations above the
LC50 of 75 nM (16), is in contrast to many chemothera-
peutic agents such as camptothecin and doxorubicin
that require less than 8 h to induce apoptosis [26,27].
This suggests that multiple events, including possibly












Figure 1 (See legend on next page.)
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Figure 1 Induction of cell death by EA in A498 RCC cells. A498 cells were cells were treated with EA at 50 and 100 nM. Control cells received
0.1% DMSO (vehicle). All conditions were performed in triplicate. Cells were then incubated with additions for 24 or 48 h before measuring
viability using the PrestoBlue® assay (A). A498 cells were treated with 100 nM EA or vehicle for 24 and 45 h durations. Apoptosis was determined
by measuring cytoplasmic histone-associated-DNA-fragments using the Cell Death Detection ELISAPLUS assay kit (B). A498 cells were treated with
100 nM EA or with 0.1% DMSO (control) for 24 and 46 h. Cells were then trypsinized, washed with ice cold PBS, and stained with Alexa Fluor®
488 annexin V and PI and analyzed by flow cytometry (C).
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will often undergo autophagy to generate nutrients for
survival [28]. Considering that EA may impose meta-
bolic stress on A498 cells, the induction of autophagy in
response to EA was determined. The induction ofFigure 2 Caspases are not activated in-EA induced cell death. A498 ce
or with 200 μM etoposide for 24 h. Cells were then harvested and stained
active caspase were then determined by fluorescence (A). A498 cells were
protein was extracted. Western blot analysis was performed using an anti-c
loading (B).authophagy was examined by three methods, independ-
ently, in A498 cells treated with EA. For the first of these
series of experiments, A498 cells were treated with 200
nM EA or 0.1% DMSO (control) for approximately 45 h.
In addition, cells were treated with rapamycin (500 nM),lls cells were treated with 100 nM EA or 0.1% DMSO (control) for 43 h,
with the FLICA reagent which only binds active caspases. Levels of
treated with 200 nM EA or with 0.1% DMSO (control) for 48 h and
aspase-3 antibody. B-actin was probed as a control for protein
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cytometry was performed using the fluorescent probe,
Cyto-ID® Green which primarily stains autolysosomes
and earlier autophagic compartments. As presented in
Figure 3A, flow cytometry analysis clearly revealed in-
creased staining of cells treated with EA (19.8% autopha-
gic) or rapamycin (12.6% autophagic) compared to
control (1.9% autophagic) cells suggesting the induction
of autophagy. Importantly, under the conditions of the
assay, EA appeared to be at least equal to rapamycin







Figure 3 EA induces autophagy in A498 cells. A498 cells were treated w
rapamycin for 20 h. Autophagy was measured by staining autolysosomes a
ID® Green. Samples were then analyzed in the green (FL1) channel of the F
0.1% DMSO (control) for 45 h and then stained with Hoechst nuclear stain
formaldehyde. The stained cells were then analyzed by fluorescence micro
and d show cells treated with EA. Nuclei are stained in blue. Autolysosome
cells were treated with 200 nM EA or with 0.1% DMSO (control) for 48 h an
an anti-LC3B antibody. B-actin was probed as a control for protein loadingexperiments, cells treated with EA as above were also
examined by fluorescence microscopy after dual staining
with Hoechst nuclear stain and Cyto-ID® Green detec-
tion reagent. The results displayed in Figure 3B show
the increased staining of EA treated cells with Cyto-ID®
Green (panel d) compared to control cells treated with
vehicle (panel c). Specifically, EA treated cells displayed
intensely stained punctate structures representing the
spherical vacuoles that accumulate in the perinuclear re-
gion, or in foci distributed though out the cytoplasm of




















ith 200 nM EA or 0.1% DMSO (control) for 46 h and with 500 nM
nd earlier autophagic compartments with the fluorescent probe Cyto-
ACS Caliber flow cytometer (A). Cells were treated with 200 nM EA or
and Cyto-ID® Green detection reagent followed by fixing with 4%
scopy. Panels a and c show cells treated with 0.1% DMSO and panels b
s and earlier autophagic compartments are stained in green (B). A498
d protein was extracted. Western blot analysis was performed using
(C).
Williams et al. Journal of Experimental & Clinical Cancer Research 2013, 32:57 Page 8 of 13
http://www.jeccr.com/content/32/1/57Figure 3B show stained nuclei of control (a) and EA
treated cells (b). The use of the Cyto-ID® Green detec-
tion reagent enabled detection and quantification of au-
tophagic cells induced by EA, however, to confirm this
action of EA at the molecular level, a well accepted indi-
cator of autophagy [32], the conversion of LC3B-I to
LC3B-II, was examined by Western blot analysis in EA
treated A498 cells. During autophagy LC3-I is converted
to LC3-II by lipidation to allow LC3 to be associated
with autophagic vesicles. As shown in Figure 3C, West-
ern blot analysis revealed the conversion of LC3B-I to
LC3B-II in EA treated A498 cells but not in control cells
confirming the presence of autophagic vesicles in EA
treated cells. Importantly, the supplementation of cul-
ture medium with nonessential amino acids (NEAA),
known inhibitors of autophagy [33,34], decreased the
level of autophagic vesicles induced by EA (100 nM) in
A498 cells (Figure 4A). The fact that there is a decrease
in EA-induced autophagic vesicles upon treatment with
NEAA, a known inhibitor of autophagy, implies that EA
induces autophagy as opposed to causing an accumula-
tion of autophagic vesicles due to reduced turnover or
transport to lysosomes [35]. Interestingly, another well
known inhibitor of autophagy, 3-methyladenine (3MA),
did not inhibit autophagy and was found to be toxic to
A498 cells at concentrations above 2.5 mM (data not
shown). This is probably due to the dual role that 3MA
has in modulating autophagy in which it can actually in-
duce autophagy depending on the temporal patterns of
inhibition of class I and III phosphoinositide 3-kinase
[36]. In summary, our results demonstrate that EA in-
duces autophagy in A498 cells which can be inhibited by
supplementing cell culture media with NEAA.
Effect of inhibition of autophagy on cell death
Having demonstrated that EA induces autophagy in
A498 cells, the question that arises is whether autophagy
is a defense mechanism or a cell death mechanism. To
answer this question, both cell viability and levels of
apoptosis were determined in independent experiments
in which A498 cells were treated with and without
NEAA (1X) in the presence and absence of 150 nM EA,
or with 200 μM VP16 for 46 h. As shown in Figure 4B,
the viability of cells treated with EA were similar to
that receiving EA plus NEAA as determined by the
PrestoBlue® assay. NEAA, alone, had no effect on the
cells when compared to control cells receiving vehicle
(0.1% DMSO), whereas, cells treated with VP16 lost via-
bility as expected. These results indicated that inhibition
of autophagy did not diminish cell death induced by EA.
We then examined the levels of apoptosis in A498 cells
treated in the same manner as in the viability experi-
ments. The results of these experiments demonstrated
that the levels of apoptosis were similar in cells treatedwith EA compared to those treated with EA plus
NEAA indicating that inhibiting autophagy does not
affect the level of apoptosis induced by EA (Figure 4C).
It is noteworthy that the level of apoptosis induced by
EA appears to be much less than that induced by VP16
(Figure 4B) even though the agents reduce cell viability
to similar levels (Figure 4A). Taken together, our results
suggest that EA-induced autophagy does not appear to
be a cell death mechanism, and is likely a defense
mechanism that ultimately fails and cells die by a
caspase-independent apoptotic cell death and by necro-
sis (Figures 1B and C).
Effect of EA on cell cycle
In order to gain insight into how EA might regulate cell
proliferation in A498 cells, the effect of EA on cell
cycle distribution was examined. In these studies, A498
cells were treated with 200 nM EA or with 0.1% DMSO
(control) for 45 h. Cells were then stained after fixing
and analyzed by flow cytometry as described under
Methods. The results from these experiments demon-
strated that cells treated with EA accumulated in the
G2 phase of the cell cycle indicating a block in G2/M
transition (Figure 5).
Effect of EA on activation of AKT, ERK, and AMP-activated
kinase
Because the AKT and ERK signaling pathways drive un-
restricted cell proliferation as well as regulate autophagy
to obtain nutrients to support rapid growth, they are
commonly activated in cancer [37]. Since EA was found
to block the cell cycle as well as induce autophagy, it is
likely that EA affects these signaling pathways. To exam-
ine this possibility, Western blot analysis was performed
after treating A498 cells with 100 nM EA or vehicle for
increasing times. The results of these experiments re-
vealed reduced levels of phosphorylation of AKT and
ERK at both 10 h and 24 h of EA treatment indicating
inhibition of both kinases by EA (Figure 6). Inhibition of
AKT activation by EA is consistent with its ability to in-
hibit growth and to induce autophagy. In contrast, acti-
vation of ERK is usually associated with induction of
autophagy [38]. Activation of AMP-activated protein
kinase (AMPK) was also examined since this kinase is a
known energy sensor and is activated when ATP levels
are low due to cell stress resulting in the induction of
autophagy [39]. Interestingly, our results did not reveal
activation of AMPK at the time points tested (Figure 6).
In summary, our results demonstrate that EA induces
cell death in A498 cells by caspase-independent apop-
tosis and necrosis while inducing autophagy. Inhibition
of autophagy does not diminish cell death by EA
suggesting that autophagy is not a cell death mechanism
and is likely a survival mechanism which ultimately fails.
Figure 4 Inhibition of autophagy does not affect EA-induced cell death. A498 cells were cultured in the presence and absence of 100 nM
EA or, with EA and 1X NEAA in combination for 44 h. Autophagy was then determined by flow cytometry after staining with Cyto-ID® (A). A498
cells were treated with 150 nM EA, 0.1% DMSO, 1X NEAA, 200 μM VP16 or with 100 nM EA plus 1X NEAA for 46 h. Cell viability was then
determined using the PrestoBlue® assay (B). A498 cells were treated as in (B) and then apoptosis was determined by measuring histone-
associated DNA fragments by ELISA (C).
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phase of the cell cycle blocking the G2/M transition.
Taken together, our results indicate that cell death byEA occurs by multiple mechanisms which are likely cell
context dependent. Because EA can elicit cell death by





Figure 5 EA blocks the G2/M transition of the cell cycle. A498 cells were treated with 200 nM EA or with 0.1% DMSO (control) for 45 h. The
cells were then fixed and stained with PI. The PI content of cells was measured by flow cytometry as described under Methods.
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effective chemotherapeutic agent that can bypass
chemo-resistance, making it ideal for the treatment of
metastatic RCC.
Discussion
Metastatic RCC is one of the most chemo-resistant can-
cers for which no curative treatment is available. Hall-
marks of this cancer include a highly hypoxic and
glycolytic nature and an increased dependency on glu-
cose, all characteristics associated with VHL loss and
HIF stabilization which play a central role in the patho-
genesis of RCC. However, the limited success of thera-
peutics targeting the VHL/HIF axis suggests that other
molecular alterations also play an important role in the
development of RCC. Since pVHL loss and HIFα
stabilization are the earliest detectable molecular events
in VHL-associated renal tumorigenesis, it is believed that
these initial changes trigger other events, both HIF-
dependent and independent, resulting in progression to
RCC. For example, increased hepatocyte growth factor
signaling through c-MET, increased susceptibility toTGF-α/EGF signaling, as well as modifications in extra-
cellular matrix turnover and remodeling are implicated
in the pathogenesis of RCC [40]. Clearly, RCC is a com-
plex disease resulting from numerous alterations of
genes and pathways that work in concert, indicating that
pursuing a single target or pathway will not yield che-
motherapeutics with significant efficacy. The best chance
for achieving therapeutic efficacy in a disease such as
RCC should involve the use of agents that target the
multiple pathways which contribute fundamentally to
this disease.
Natural products are well known to affect multiple tar-
gets and thus have excellent potential as chemothera-
peutic agents. The relatively recently identified natural
product, englerin (EA), is very unique due to its high se-
lectivity against RCC that is 1000-fold higher than any
other cell type [16]. Our results demonstrate that EA in-
duces apoptosis and autophagy in addition to necrosis in
A498 RCC cells at nanomolar concentrations. This find-
ing is in contrast to a recent report stating that EA in-
duced necrosis but not apoptosis or autophagy [22]. In








































Figure 6 EA inhibits activation of AKT and ERK kinsases. A498
cells were cultured with 100 nM EA or with 0.1% DMSO (control) for
the indicated times and protein was Isolated. Western blot analysis
was performed as described under Methods using antibodies
against AKT, ERK, and AMPK and their phosphorylated counterparts.
B-actin was probed to control for protein loading. (+) control; Jurkat
cell extract.
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with non-essential amino acids (NEAA), a known inhibi-
tor of autophagy [41], and was thus not observed. Our
results confirmed that autophagy induced by EA could
be inhibited by NEAA. We further showed that inhib-
ition of autophagy by NEAA did not diminish cell death.
This finding is supported by the previous study which
showed that RCC cells died under conditions which
inhibited autophagy with a sensitivity to EA similar to
that observed by us and others [16,21]. For instance, in
viability assays in the study by Sulzmaier et al. [22], EA
was found to have an EC50 of 53 nM in the presence of
NEAA. In the absence of NEAA, the estimated EC50 of
EA in A498 cells in our viability assay was 63 nM
(Figure 1 and data not shown). Furthermore, the NCI
reported LC50 for EA in A498 cells, under conditions
not inhibiting autophagy, was 79 nM [16]. Though the
NCI determined LC50 is a somewhat different measure
than the EC50, determined by us and Sulzmaier et al.
[22], in addition to the assays being different, the fact
that these values are not very different regardless ofwhether autophagy is inhibited, indicates that autophagy
does not appear to have much of an effect on cell death.
Though autophagy can play a pro-death role when
prolonged or in certain developmental conditions [42],
in most circumstances, autophagic generation of nutri-
ents prevents or delays cell death [43], thus acting as a
survival mechanism. It is, in fact, fairly common for can-
cer cells experiencing stress of different origin to activate
autophagy in an attempt to alleviate stress and survive
[44]. It is for this reason, that the autophagic machinery
has become a therapeutic target. Inhibiting autophagy in
tumor cells exposed to cytotoxic agents often results in
increased apoptotic cell death [45]. However, we have
not observed this in the context of EA-induced apop-
tosis as the levels of apoptosis were not altered by the
inhibition of autophagy by NEAA (Figure 4). It is not
entirely clear what role EA-induced autophagy plays in
in A498 cells, but it does not appear to represent a cell
death mechanism in this context, and most likely is a
survival mechanism that ultimately fails.
Although EA induced apoptosis in A498 RCC cells, it
did not appear to be a strong inducer of apoptosis
as compared to other agents such as VP16 and
camptothecin (Figure 4 and data not shown). Interest-
ingly, the report by Sulzmaier et al. [22] concluded that
EA did not induce apoptosis in these cells. However, by
analyzing not only external exposure of phosphatidyl
serine, but also by examining histone-associated DNA
fragments, we found that EA did induce some level of
apoptosis in A498 cells. The induction of apoptosis by
EA was independent of caspase activation suggesting the
involvement of non caspase proteases such as cathepsins
and calpains [46]. It is likely that the induction of apop-
tosis by EA is cell context dependent and, thus, may not
be induced in all RCC cells, especially, considering that
certain cells may have an apoptotic block. In such a case,
EA may induce other mechanisms of cell death such as
necrosis as observed by Sulzmaier et al. [22]. Our results
indicated that EA also induced necrosis as determined
by PI staining (Figure 1C). Taken together, our results
indicate that EA can induce cell death by multiple mech-
anisms and that the predominant mechanism will de-
pend on cell context.
In addition to inducing cell death, EA also induced a
block in the G2/M transition of the cell cycle in A498
cells. This indicated that EA may likely regulate cell
cycle regulatory genes and affect pathways associated
with cell proliferation. In fact, our results indicated that
EA inhibited activation of both AKT and ERK, members
of two pathways commonly activated in cancer, often to-
gether [37], and which are associated with unrestricted
cellular proliferation and decreased sensitivity to
apoptosis-inducing agents [47]. It is known that inhib-
ition of either pathway alone has a negligible effect on
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ways share downstream targets [48]. The fact that EA
can inhibit activation of both pathways suggests that it
would be an effective agent in inhibiting tumor growth.
This possibility is supported by the findings of a very re-
cent study of EA in athymic mice bearing 786–0 (renal)
tumor xenografts [23]. The results of this study demon-
strated that EA markedly inhibited tumor growth over a
two week period when administered daily at 5 mg/kg in-
traperitoneally. This study further showed that tumors
excised from the EA-treated mice revealed increased in-
hibitory phosphorylation of the insulin receptor sub-
strate 1 (IRS1) and decreased activity of the PI3/AKT
pathway, in line with our in vitro results in A498 cells.
Based on their in vitro results, the authors of this study
concluded that EA bound and activated PKCθ to inhibit
insulin signaling while, concurrently, activating HSF1, a
known inducer of glucose dependence, thus, starving
cells of glucose while promoting glucose addiction.
However, because the in vitro binding studies with EA
and PKCθ were indirect without any binding kinetic
analyses, it is unclear if PKCθ is a primary target of EA.
Furthermore, the experiments demonstrating inhibition
of glucose uptake by EA were performed using EA at
10 μM, a concentration of EA approximately 200-fold
higher than its IC50. It is well established that when cells
are starved, the energy sensor, AMP-activated protein
kinase, becomes activated by phosphorylation resulting
in the induction of autophagy. If EA inhibits glucose up-
take, it would be expected to result in a higher ADP/
ATP and AMP/ATP ratio and consequent activation of
AMPK. Our results, however, did not reveal activation
of AMPK by EA at a concentration of 100 nM, a con-
centration that is highly cytotoxic to A498 cells. Hence,
it is possible that the effects of EA on glucose uptake
may occur at micro molar concentrations that are much
higher than required for cell death (nanomolar) and
could represent off-target effects. Moreover, as a natural
product, EA would be expected to have multiple targets
and most likely has targets in addition to PKCθ. Such
targets may include those associated with the ER stress
since it is well established that ER stress results in the
induction of cell death and autophagy [49]. An example
of agent that induces autophagy and cell death by indu-
cing ER stress in RCC includes STF-62247 which targets
VHL-deficient RCC [50]. EA may target proteins within
the Golgi complex analogous to carminomycin I, a nat-
ural product with selective toxicity to VHL-deficient
CC-RCC [51].
In conclusion, EA induces cell death via multiple
mechanisms and likely has multiple cellular targets. The
identification of these targets and pathways affected by
this unique agent will be invaluable in understanding the
high RCC- selectivity of EA and allow development ofhighly effective chemotherapeutics for the treatment of
metastatic RCC, a highly treatment resistant cancer.
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